普拉克索治疗帕金森病患者非运动症状随机对照临床试验  

Clinical RCT of Pramipexole on Non- Motor Symptoms of Parkinson's Disease

作　　者：柏峻霞[1] 王义兰[1] 李梁蜜[1] 李承[1] 蒋安杰[1] 范文辉[1] 冯裕星[1] 

机构地区：[1]重庆市第九人民医院,重庆400700

出　　处：《中国药业》2016年第8期59-61,共3页China Pharmaceuticals

基　　金：重庆市卫生局医学科研项目;项目编号:渝卫科教[2014]56号:20142175

摘　　要：目的观察普拉克索治疗帕金森病(PD)患者非运动症状的临床疗效。方法将PD非运动症状患者102例随机分为对照组50例和试验组52例,对照组患者给予多巴丝肼治疗,试验组患者在对照组基础上加用普拉克索治疗,两组患者均以连续服用12周为1个疗程。采用非运动症状筛查问卷(NMSQuest)、汉密尔顿抑郁量表(HAMD)、帕金森病睡眠量表(PDSS)、简易精神状态量表(MMSE)及帕金森病自主神经症状量表(SCOPA-AUT)对患者的非运动症状发生情况、抑郁状况、睡眠状况、认知功能及自主神经功能障碍程度进行评定。结果试验组NMSQuest总分、HAMD及PDSS评分均较对照组显著改善(P<0.05),而MMSE与SCOPA-AUT评分两组间无统计学差异(P>0.05)。结论普拉克索能改善PD患者的部分非运动症状,如抑郁状态和睡眠障碍,但对认知功能和自主神经功能障碍无明显改善作用。Objective To investigative the efficacy of pramipexole on non- motor symptoms of Parkinson＇s disease（PD）. Methods 102 PD patients with non- motor symptom were randomly divided into the experimental group and the control group,in which 50 patients in the control group were given benserazid,52 patients in the experimental group were given both benserazid and pramipexole. 12 weeks were 1 course of treatment. Both groups were evaluated using a non-motor symptoms questionnaire（NMSQuest）,the Hamilton depression scale（HAMD）,the Pediatric Daytime Sleepiness Scale（PDSS）,the mini-mental state examination（MMSE）and the scale for outcomes in PD for autonomic symptoms（SCOPA-AUT）before and after treatment. Results The NMSQuest,HAMD and PDSS score in the experi- mental group was significantly improved than the control group（P 〈 0. 05 ） , while MMSE and COPA-AUT score in the two groups were not significantly different （P 〉 0. 05）. Conclusion Pramipexole can improve some of non- motor symptoms, including depression and sleeping disorder,but is not effective for cognition and autonomic nerve function disorder.

关 键 词：帕金森病 非运动症状 普拉克索 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R971.5[医药卫生—药学]